Study of Cemiplimab Combined With Dabrafenib and Trametinib for Anaplastic Thyroid Cancer

Inclusion Criteria

• Diagnosed with anaplastic thyroid cancer that has a specific BRAF-V600E mutation.
• Cancer must be either spread to other parts of the body or cannot be surgically removed.
• A doctor should confirm that the cancer cannot be removed by surgery.
• Must have at least one tumor that can be measured by scans or exams.
• Must be 18 years or older.
• Must be in good general health, able to perform daily activities with minimal restrictions.
• Must be able to swallow pills.
• Must have normal blood and organ function based on specific medical tests.
• Women of childbearing potential must have a negative pregnancy test and agree to use birth control during the study.
• Must agree to have 2-4 biopsies of the cancer.
• Must understand and agree to sign a consent form to participate.

Exclusion Criteria

• Have previously been treated with dabrafenib and trametinib, unless specific exceptions apply.
• Have active cancer spread to the brain, unless approved by the study doctor.
• Have lung diseases like interstitial lung disease or pneumonitis.
• Have a history of certain eye conditions like retinal vein occlusion.
• Have heart problems, such as uncontrolled arrhythmias or recent heart attacks.
• Have active hepatitis B or C infections.
• Have HIV and are on antiretroviral therapy.
• Have other serious illnesses that would prevent following the study requirements.
• Cannot receive immunotherapy due to past severe reactions or active autoimmune diseases.
• Have a history of organ transplants or active tuberculosis.